{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-26-000023","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2026-09-21T20:34:25+00:00","discovered_at":"2026-09-21T20:37:26.839961+00:00","generated_at":"2026-09-21T20:37:35.328949+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PTC completes acquisition of ST-920 Fabry gene therapy from Sangamo; BLA submission expected Q4 2026","bullets":["Completed acquisition of ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics.","Rolling BLA submission to FDA for accelerated approval expected to be completed in Q4 2026.","BLA based on 52-week Phase 1/2 STAAR study showing favorable renal function effect and safety/tolerability.","Company also plans to pursue regulatory approval of ST-920 outside the United States.","CEO Matthew Klein cites potential to address limitations of chronic enzyme replacement therapy for Fabry community."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-26-000023","json":"https://secwatch.observer/filing/0001070081-26-000023.json","markdown":"https://secwatch.observer/filing/0001070081-26-000023.md","text":"https://secwatch.observer/filing/0001070081-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/0001070081-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/tmb-20260921x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-21T20:37:35.328949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}